Literature DB >> 31407397

The effects of hyperuricemia on the differentiation and proliferation of osteoblasts and vascular smooth muscle cells are implicated in the elevated risk of osteopenia and vascular calcification in gout: An in vivo and in vitro analysis.

Bing Yan1, Dongmei Liu2, Jie Zhu2, Xiaoling Pang2.   

Abstract

BACKGROUND: In this study, we established both an animal model and a cellular model of hyperuricemia (HUC). Subsequently, we treated these models with allopurinol (ALLO) to study the effect of uric acid (UA) and ALLO on the differentiation and proliferation of osteoblasts and vascular smooth muscle cells (VSMC).
METHODS: Western Blot, immunohistochemistry assay, and real-time polymerase chain reaction were conducted to measure the changes in the expression of differentiation-related factors in osteoblasts and VSMCs in HUC and HUC+ALLO groups. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay and flow cytometry were utilized to observe the changes in the proliferation of osteoblasts in HUC and HUC+ALLO groups. Von Kossa staining was performed along with calcium content measurement to investigate the effect of HUC/ALLLO on vascular calcification.
RESULTS: In this study, the levels of Wnt3a and differentiation-related factors, including Runx2, Sp7, Ibsp, Bglap, Dmp1, and Col1a1, were all evidently decreased in HUC rats, while the presence of ALLO increased the levels of above factors. In addition, the viability of osteoblasts was reduced while their apoptosis was elevated in the HUC group, and ALLO treatment reduced the apoptosis and increased the viability of osteoblasts to a certain extent. Moreover, HUC elevated the levels of Wnt3a, Runx2, Sp7, Bglap, Col1a1, SM22a, and Acta2 in VSMCs of HUC rats, leading to greatly increased calcium content and obvious vascular calcification. In contrary, ALLO treatment reduced the effect of HUC. Furthermore, the effect of UA and ALLO on osteoblasts and VSMCs was also validated in cellular models treated with monosodium urate (MSU) crystals or MSU+ALLO.
CONCLUSIONS: HUC can suppress the differentiation and proliferation of osteoblasts while promoting the differentiation of VSMCs both in vivo and in vitro. The treatment by ALLO exhibited a therapeutic effect on HUC by promoting the differentiation and proliferation of osteoblasts while reducing vascular calcification.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  differentiation; gout; hyperuricemia; osteoblasts; proliferation; vascular smooth muscle cells

Mesh:

Substances:

Year:  2019        PMID: 31407397     DOI: 10.1002/jcb.29272

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  5 in total

Review 1.  Inflammatory Response to Regulated Cell Death in Gout and Its Functional Implications.

Authors:  Jianan Zhao; Kai Wei; Ping Jiang; Cen Chang; Lingxia Xu; Linshuai Xu; Yiming Shi; Shicheng Guo; Yu Xue; Dongyi He
Journal:  Front Immunol       Date:  2022-04-06       Impact factor: 8.786

Review 2.  Uremic Vascular Calcification: The Pathogenic Roles and Gastrointestinal Decontamination of Uremic Toxins.

Authors:  Chia-Ter Chao; Shih-Hua Lin
Journal:  Toxins (Basel)       Date:  2020-12-21       Impact factor: 4.546

3.  Serum Uric Acid Level Is Positively Associated With Higher Bone Mineral Density at Multiple Skeletal Sites Among Healthy Qataris.

Authors:  Wisam Nabeel Ibrahim; Nadin Younes; Zumin Shi; Marawan Abdelhamid Abu-Madi
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-31       Impact factor: 5.555

4.  Daprodustat Accelerates High Phosphate-Induced Calcification Through the Activation of HIF-1 Signaling.

Authors:  Andrea Tóth; Dávid Máté Csiki; Béla Nagy; Enikő Balogh; Gréta Lente; Haneen Ababneh; Árpád Szöőr; Viktória Jeney
Journal:  Front Pharmacol       Date:  2022-02-07       Impact factor: 5.810

Review 5.  Uremic Toxins and Vascular Calcification-Missing the Forest for All the Trees.

Authors:  Nikolas Rapp; Pieter Evenepoel; Peter Stenvinkel; Leon Schurgers
Journal:  Toxins (Basel)       Date:  2020-09-29       Impact factor: 4.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.